|
[1]LAFARO KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17.
|
|
[2]LIU HC.Interpretation of guidelines for the treatment of primary liver cancer in China[J].J Hepatobiliary Surg,2013,21(1):12-14.(in Chinese)刘会春.中国原发性肝癌治疗指南解读[J].肝胆外科杂志,2013,21(1):12-14.
|
|
[3]FOMER A,DIAZ-GONZALEZ A,LICCIONI A,et al.Prognosis prediction and staging[J].Best Pract Res Clin Gastroenterol,2014,28(5):855-865.
|
|
[4]MA L,CHUA MS,ANDRISANI O,et al.Epigenetics in hepatocellular carcinoma:an update and future therapy perspectives[J].World J Gastroenterol,2014,20(2):333-345.
|
|
[5]MANDAVIVA PR,STOLK L,HEIL SG.Homocysteine and DNA methylation:a review of animal and human literature[J].Mol Genet Metab,2014,113(4):243-252.
|
|
[6]LUJAMBIO A,ESTELLER M.Cp G island hypermethylation of tumor suppressor microRNAs in human cancer[J].Cell Cycle,2007,6(12):1455-1459.
|
|
[7]FONG CY,MORISON J,DAWSON MA.Epigenetics in the hematologic malignancies[J].Haematologica,2014,99(12):1772-1783.
|
|
[8]ANESTOPOULOS I,VOULGARIDOU GP,GEORGAKILAS AG,et al.Epigenetic therapy as a novel approach in hepatocellular carcinoma[J].Pharmacol Ther,2015,145:103-119.
|
|
[9]POGRIBNY IP,RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Lett,2014,342(2):223-230.
|
|
[10]CHEN QW,ZHU XY,LI YY,et al.Epigenetic regulation and cancer(review)[J].Oncol Rep,2014,31(2):523-532.
|
|
[11]YAO JY,ZHANG L,ZHANG X,et al.H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells[J].J Biol Chem,2010,285(24):18828-18837.
|
|
[12]YU YL,SU KJ,HSIEH YH,et al.Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma[J].PLo S One,2013,8(9):e74870.
|
|
[13]YUAN H,LI AJ,MA SL,et al.Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells[J].World J Gastroenterol,2014,20(17):4953-4962.
|
|
[14]TURATO C,SIMONATO D,QUARTA S,et al.MicroRNAs and Serpin B3 in hepatocellular carcinoma[J].Life Sci,2014,100(1):9-17.
|
|
[15] POGRIBNY IP,RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Lett,2014,342(2):223-230.
|
|
[16]MLLER AM,FLOREK M.5-Azacytidine/5-Azacitidine[J].Recent Results Cancer Res,2014,201:299-324.
|
|
[17]VALDESPINO-GOMEZ VM,VALDESPINO-CASTILLO VE.Targeted epigenetic therapy of cancer.Achievements and perspectives[J].Cir Cir,2012,80(5):470-480.
|
|
[18]BYUN HM,CHOI SH,LAIRD PW,et al.2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine:a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1[J].Cancer Lett,2008,266(2):238-248.
|
|
[19]GNYSZKA A,JASTRZEBSKI Z,FLIS S.DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer[J].Anticancer Res,2013,33(8):2989-2996.
|
|
[20]CORADINI D,SPERANZA A.Histone deacetylase inhibitors for treatment of hepatocellular carcinoma[J].Acta Pharmacol Sin,2005,26(9):1025-1033.
|
|
[21]ZHANG J,ZHONG Q.Histone deacetylase inhibitors and cell death[J].Cell Mol Life Sci,2014,71(20):3885-3901.
|
|
[22]WANG HG,HUANG XD,SHEN P,et al.Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro[J].Int J Mol Med,2013,31(4):967-974.
|
|
[23]DE CONTI A,TRYNDYAK V,KOTURBASH I,et al.The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway[J].Carcinogenesis,2013,34(8):1900-1906.
|
|
[24]WEST AC,JOHNSTONE RW.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest,2014,124(1):30-39.
|
|
[25]YEO W,CHUNG HC,CHAN SL,et al.Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma:a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group[J].J Clin Oncol,2012,30(27):3361-3367.
|
|
[26] PARK JK,KOGURE T,NUOVO GJ,et al.miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J].Cancer Res,2011,71(24):7608-7616.
|
|
[27]CALLEGARI E,ELAMIN BK,GIANNONE F,et al.Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model[J].Hepatology,2012,56(3):1025-1033.
|
|
[28]MENG XZ,ZHENG TS,CHEN X,et al.MicroRNA expression alteration after arsenic trioxide treatment in Hep G-2 cells[J].J Gastroenterol Hepatol,2011,26(1):186-193.
|
|
[29]NAKAO K,MIYAAKI H,ICHIKAWA T.Antitumor function of microRNA-122 against hepatocellular carcinoma[J].J Gastroenterol,2014,49(4):589-593.
|
|
[30]GREENHILL C.Hepatocellular carcinoma:new insight into angiogenesis in hepatocellular carcinoma:involvement of microRNA-26a[J].Nat Rev Gastroenterol Hepatol,2014,11(1):3.
|
|
[31]LU Y,YUE X,CUI Y,et al.MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3[J].Biochem Biophys Res Commun,2013,441(4):873-879.
|
|
[32]RAGGI C,FACTOR VM,SEO D,et al.Epigenetic reprogramming modulates malignant properties of human liver cancer[J].Hepatology,2014,59(6):2251-2262.
|
|
[33]HSU FT,LIU YC,CHIANG IT,et al.Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappa B signaling[J].Int J Oncol,2014,45(1):177-188.
|
|
[34]LU YS,CHOU CH,TZEN KY,et al.Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(2):e181-e189.
|
DownLoad: